Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest DelMar Pharmaceuticals Inc. Stories

2013-11-22 08:23:18

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 22, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18(th) Annual Society for Neuro-Oncology (SNO) meeting in San Francisco. Enrollment in the...

2013-11-14 08:33:50

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 14, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced that the Company will present interim clinical trial data for VAL-083 in glioblastoma at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18(th) Annual Society for Neuro-Oncology (SNO) meeting. The WFNO/SNO meeting will take place November 21(st)...

2013-10-21 08:29:07

VAL-083 therapeutic activity seen in glioblastoma, chronic myelogenous leukemia and non-small cell lung cancer VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 21, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting. The data presented today, along with historical research by the U.S....

2013-10-15 08:31:13

VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 15, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" or "DelMar Pharma") today announced that the company would present an abstract entitled "The unique mechanism of action of VAL-083 may provide a new treatment option for some chemo-resistant cancers" at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held October 19 to 23, 2013 at the Hynes...

2013-10-09 08:27:04

Glioblastoma multiforme (GBM) Phase 1b clinical trial is ongoing for VAL-083, a chemotherapy that has been well-studied by the National Institutes of Health VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 9, 2013 /PRNewswire/ -- The president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") Jeffrey Bacha spoke to Life Science IP Review (LSIPR) about developing new intellectual property (IP) for their lead drug candidate, VAL-083, a new therapy in...

2013-09-19 08:28:34

Glioblastoma is the most common form of brain cancer, and DelMar is developing VAL-083 in the U.S. and China to treat aggressive cancers VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 19, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") today announced a discussion on CEOLIVE.TV by Jeffrey Bacha, president and CEO of DelMar Pharma, a cancer-focused company developing new therapies for patients with little to no treatment options....

2013-09-16 12:28:09

Company invites individual and institutional investors to log-on to view presentation NEW YORK, Sept. 16, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that their September 12th RetailInvestorConferences.com presentation is now available for on-demand viewing. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat glioblastoma...

2013-09-09 08:27:39

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK, Sept. 9, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat...

2013-09-09 08:27:28

Advisory Board to Oversee Clinical Studies in China to Support Product Growth and Repositioning of VAL-083 VANCOUVER, British Columbia, MENLO PARK, Calif., and WUZHOU, China, Sept. 9, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") and Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd., a subsidiary of Guagxi Wuzhou Zhongeng Group Co., Ltd. (SHG 600252) today announced that the companies have established a clinical advisory board to oversee new clinical studies aimed...

2013-09-03 08:27:46

DelMar Developing VAL-083 in U.S. and China to Treat Aggressive Cancers VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 15(th) Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Monday, September 9(th) at 3:15 p.m. EDT in Room 7.02 at the...